Top

International Ophthalmology

Published in:

01-04-2019 | Cryotherapy | Review

Recent advances in the diagnosis and treatment of Coats’ disease

Published in: International Ophthalmology | Issue 4/2019

Abstract

Purpose

To review and summarize the recent progress in the diagnosis and treatment of Coats’ disease.

Methods

Literature was collected from Web of Science, Medline and Pubmed, through searching of these keywords: “Coats’ disease”, “diagnosis” and “treatment”.

Results

Coats’ disease is characterized by idiopathic leaky retinal vascular telangiectasia and microvascular abnormalities often accompanied by intraretinal or subretinal exudation and retinal detachment. Neovascular glaucoma and phthisis bulbi often occur in advanced cases. Coats’ disease has significant diversity in terms of its clinical presentation and morphology. Anti-VEGF therapy combined with laser photocoagulation for early Coats’ disease and anti-VEGF therapy combined with minimally invasive vitrectomy for advanced Coats’ disease can achieve good efficacy.

Conclusion

Early diagnosis and timely treatment based on clinical stage are critical to retaining the patient’s visual function. Patients should be aware that close long-term follow-up is necessary.

Ghorbanian S, Jaulim A, Chatziralli IP (2012) Diagnosis and treatment of coats’ disease: a review of the literature. Ophthalmologica 227:175–182. https://doi.org/10.1159/000336906 CrossRefPubMed

Grosso A, Pellegrini M, Cereda MG, Panico C, Staurenghi G, Sigler EJ (2015) Pearls and pitfalls in diagnosis and management of coats disease. Retina 35:614–623. https://doi.org/10.1097/IAE.0000000000000485 CrossRefPubMed

Morris B, Foot B, Mulvihill A (2010) A population-based study of Coats disease in the United Kingdom I: epidemiology and clinical features at diagnosis. Eye 24:1797–1801. https://doi.org/10.1038/eye.2010.126 CrossRefPubMed

Peng J, Zhang Q, Chen C, Huang Q, Li Y, Zhao P (2017) Early onset coats’ disease initially treated as unilateral ROP at 39 weeks postmenstrual age: a case report. BMC Ophthalmol 17:145. https://doi.org/10.1186/s12886-017-0536-x CrossRefPubMedPubMedCentral

Charles PLF (2014) Coats disease in a 3-week-old boy. J AAPOS 18:86–88. https://doi.org/10.1016/j.jaapos.2013.08.013 CrossRef

Alqahtani AA, Almasaud JM, Ghazi NG (2015) Clinical characteristics and treatment outcomes of coats disease in a Saudi Arabian population. Retina 35:2091–2099. https://doi.org/10.1097/IAE.0000000000000594 CrossRef

Stanga PE, Romano F, Chwiejczak K, Tsamis E, Stringa F, Biswas S et al (2017) Swept-source optical coherence tomography angiography assessment of fellow eyes in coats disease. Retina. https://doi.org/10.1097/iae.0000000000001995 CrossRef

Blair MP, Ulrich JN, Elizabeth HM, Shapiro MJ (2013) Peripheral retinal nonperfusion in fellow eyes in coats disease. Retina 33:1694–1699. https://doi.org/10.1097/IAE.0b013e318285cb86 CrossRefPubMed

Nucci P (2017) Coats’ disease: not such a smooth ride. Graefes Arch Clin Exp Ophthalmol 255:1879–1880. https://doi.org/10.1007/s00417-017-3796-5 CrossRefPubMed

10.

Rabiolo A, Marchese A, Sacconi R, Cicinelli MV, Grosso A, Querques L et al (2017) Refining Coats’ disease by ultra-widefield imaging and optical coherence tomography angiography. Graefes Arch Clin Exp Ophthalmol 255:1881–1890. https://doi.org/10.1007/s00417-017-3794-7 CrossRefPubMed

11.

Daruich A, Matet A, Munier FL (2017) Younger age at presentation in children with coats disease is associated with more advanced stage and worse visual prognosis: a retrospective study. Retina 38:2239–2246. https://doi.org/10.1097/IAE.0000000000001866 CrossRef

12.

Daruich A, Matet A, Munier FL (2018) Cataract development in children with Coats disease: risk factors and outcome. J Am Assoc Pediatr Ophthalmol Strabismus 22:44–49. https://doi.org/10.1016/j.jaapos.2017.09.009 CrossRef

13.

Stacey AW, Borri M, Francesco SD, Antenore AS, Menicacci F, Hadjistilianou T (2016) A case of anterior chamber cholesterolosis due to coats’ disease and a review of reported cases. Open Ophthalmol J 10:27–32. https://doi.org/10.2174/1874364101610010027 CrossRefPubMedPubMedCentral

14.

Asaad SZ, Hussain N (2018) Adult coats disease presenting as subfoveal nodule. Case Rep Ophthalmol 9:232–237. https://doi.org/10.1159/000487707 CrossRefPubMedPubMedCentral

15.

Daruich AL, Moulin AL, Tran HV, Matet A, Munier FL (2016) Subfoveal nodule in Coats’ disease: toward an updated classification predicting visual prognosis. Retina 37:1591–1598. https://doi.org/10.1097/IAE.0000000000001399 CrossRef

16.

Shields JA, Shields CL, Honavar SG, Demirci H, Cater J (2001) Classification and management of Coats disease: the 2000 Proctor Lecture. Am J Ophthalmol 131:572–583CrossRefPubMed

17.

Senft SH, Hidayat AA, Cavender JC (1994) Atypical presentation of Coats disease. Retina 14:36–38CrossRefPubMed

18.

Fernandes BF, Odashiro AN, Maloney S, Zajdenweber ME, Lopes AG Jr, Burnier MN (2006) Clinical-histopathological correlation in a case of Coats’ disease. Diagn Pathol 1:24. https://doi.org/10.1186/1746-1596-1-24 CrossRefPubMedPubMedCentral

19.

Zhao Q, Peng XY, Yang WL, Li DJ, You QS, Jonas JB (2016) Coats’ disease and retrobulbar haemodynamics. Acta Ophthalmol 94:397–400. https://doi.org/10.1111/aos.12921 CrossRefPubMed

20.

Lim WK, Nussenblatt RB, Chan CC (2005) Immunopathologic features of inflammatory coats disease. Arch Ophthalmol 123:279–281. https://doi.org/10.1001/archopht.123.2.279 CrossRefPubMed

21.

Kase S, Mori S, Noda K, Ishida S (2018) Anterior proliferative vitreoretinopathy in a patient with Coats disease. Int J Ophthalmol. https://doi.org/10.18240/ijo.2018.02.28

22.

Ghassemi F, Shields CL, Mohebbi M, Nili Ahmadabadi M, Morsali F, Sabour S (2017) Serum hypercoagulability states in Coats’ disease. Clin Ophthalmol 11:305–310. https://doi.org/10.2147/opth.s121375 CrossRefPubMedPubMedCentral

23.

Zhao Q, Peng XY, Chen FH, Zhang YP, Wang L, You QS et al (2014) Vascular endothelial growth factor in Coats’ disease. Acta Ophthalmol 92:e225–228. https://doi.org/10.1111/aos.12158 CrossRefPubMed

24.

Zhang H, Liu ZL (2012) Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats’ disease. J Ocul Pharmacol Ther 28:397–401. https://doi.org/10.1089/jop.2011.0168 CrossRefPubMed

25.

Yang Q, Lu H, Song X, Li S, Wei W (2016) iTRAQ-based proteomics investigation of aqueous humor from patients with Coats’ disease. PLoS ONE 11:e0158611. https://doi.org/10.1371/journal.pone.0158611 CrossRefPubMedPubMedCentral

26.

Black GCM, Perveen R, Bonshek R, Cahill M, Claytonsmith J, Christopher Lloyd I et al (1999) Coats’ disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Genet 8:2031–2035CrossRef

27.

Peene G, Smets E, Legius E, Cassiman C (2018) Unilateral Coats’-like disease and an intragenic deletion in the TERC gene: a case report. Ophthalmic Genet 39:247–250. https://doi.org/10.1080/13816810.2017.1401086 CrossRefPubMed

28.

Saatci AO, Ayhan Z, Yaman A, Bora E, Ulgenalp A, Kavukcu S (2018) A 12-year-old girl with bilateral coats disease and ABCA4 gene mutation. Case Rep Ophthalmol 9:375–380. https://doi.org/10.1159/000492320 CrossRefPubMedPubMedCentral

29.

Robitaille JM, Zheng B, Wallace K, Beis MJ, Tatlidil C, Yang J et al (2011) The role of Frizzled-4 mutations in familial exudative vitreoretinopathy and Coats disease. Br J Ophthalmol 95:574. https://doi.org/10.1136/bjo.2010.190116 CrossRefPubMed

30.

Den Hollander AI, Davis J, Van DVV, Saskia D, Zonneveld MN, Pierrottet CO, Koenekoop RK et al (2010) CRB1 mutation spectrum in inherited retinal dystrophies. Hum Mutat 24:355CrossRef

31.

Sohn EH, Michaelides M, Bird AC, Roberts CJ, Moore AT, Smyth D et al (2011) Novel mutation in PANK2 associated with retinal telangiectasis. Br J Ophthalmol 95:149–150. https://doi.org/10.1136/bjo.2010.183616 CrossRefPubMed

32.

Wu J-H, Liu J-H, Ko Y-C, Wang C-T, Chung Y-C, Chu K-C et al (2016) Haploinsufficiency of RCBTB1 is associated with Coats disease and familial exudative vitreoretinopathy. Hum Mol Genet 25:1637–1647. https://doi.org/10.1093/hmg/ddw041 CrossRef

33.

Yonekawa Y, Todorich B, Trese MT (2016) Optical coherence tomography angiography findings in coats’ disease. Ophthalmology 123:1964–1964. https://doi.org/10.1016/j.ophtha.2016.05.004 CrossRefPubMed

34.

Ong SS, Mruthyunjaya P, Stinnett S, Vajzovic L, Toth CA (2018) Macular features on spectral-domain optical coherence tomography imaging associated with visual acuity in coats’ disease. Invest Ophthalmol Vis Sci 59:3161–3174. https://doi.org/10.1167/iovs.18-24109 CrossRefPubMedPubMedCentral

35.

Hautz W, Golebiewska J, Kocyla-Karczmarewicz B (2017) Optical coherence tomography and optical coherence tomography angiography in monitoring coats’ disease. J Ophthalmol 2017:1–8. https://doi.org/10.1155/2017/7849243 CrossRef

36.

Eisenberg L, Castillo M, Kwock L, Mukherji SK, Wallace DK (1997) Proton MR spectroscopy in Coats disease. AJNR Am J Neuroradiol 18:727–729PubMed

37.

Koozekanani DD Jr, Connor TB, Wirostko WJ (2012) RetCam II fluorescein angiography to guide treatment and diagnosis of Coats disease. Ophthalmic Surg Lasers Imaging. https://doi.org/10.3928/15428877-20100215-86 CrossRef

38.

Kumar V, Chandra P, Kumar A (2017) Ultra-wide field imaging in the diagnosis and management of adult-onset Coats’ disease. Clin Exp Optom 100:79–82. https://doi.org/10.1111/cxo.12418 CrossRefPubMed

39.

Tsui I, Franco-Cardenas V, Hubschman JP, Schwartz SD (2013) Pediatric retinal conditions imaged by ultra wide field fluorescein angiography. Ophthalmic Surg Lasers Imaging 44:59–67. https://doi.org/10.3928/23258160-20121221-14 CrossRef

40.

Jung EH, Kim JH, Kim SJ, Yu YS (2018) Fluorescein angiographic abnormalities in the contralateral eye with normal fundus in children with unilateral Coats’ disease. Korean J Ophthalmol 32:65–69. https://doi.org/10.3341/kjo.2016.0092 CrossRefPubMedPubMedCentral

41.

Suzani M, Moore AT (2015) Intraoperative fluorescein angiography-guided treatment in children with early Coats’ disease. Ophthalmology 122:1195–1202. https://doi.org/10.1016/j.ophtha.2015.02.002 CrossRefPubMed

42.

Shields CL, Uysal Y, Benevides R Jr, Malloy B, Shields JA (2006) Retinoblastoma in an eye with features of Coats’ disease. J Pediatr Ophthalmol Strabismus 43:313–315PubMed

43.

Mutha V, Agrawal S, Chandra P, Kumar A (2018) Coats disease with exudative retinal detachment simulating cysticercus cyst: misleading ultrasonography! BMJ Case Rep. https://doi.org/10.1136/bcr-2017-222975 CrossRefPubMed

44.

Michaelides M, Luthert PJ, Cooling R, Firth H, Moore AT (2004) Norrie disease and peripheral venous insufficiency. Eur Heart J 88:1475. https://doi.org/10.1136/bjo.2004.042556 CrossRef

45.

Rugwizangoga B, Mwabili T, Scanlan T, Meyer P, Kitinya J (2014) Coats’ disease in Tanzania: first case report and literature review. Afr Health Sci 14:763–768. https://doi.org/10.4314/ahs.v14i3.37 CrossRefPubMedPubMedCentral

46.

Sigler EJ, Randolph JC, Calzada JI, Wilson MW, Haik BG (2014) Current management of Coats disease. Surv Ophthalmol 59:30–46. https://doi.org/10.1016/j.survophthal.2013.03.007 CrossRefPubMed

47.

Ong SS, Buckley EG, McCuen BW 2nd, Jaffe GJ, Postel EA, Mahmoud TH et al (2017) Comparison of visual outcomes in Coats’ disease: a 20-year experience. Ophthalmology 124:1368–1376. https://doi.org/10.1016/j.ophtha.2017.03.051 CrossRefPubMed

48.

Nuzzi R, Lavia C, Spinetta R (2017) Paediatric retinal detachment: a review. Int J Ophthalmol 10:1592–1603. https://doi.org/10.18240/ijo.2017.10.18 CrossRefPubMedPubMedCentral

49.

Lambert NG, Hoffman RO, Hartnett ME (2016) A case of Coats disease and concurrent anisometropic amblyopia. Am J Ophthalmol Case Rep 4:21–23. https://doi.org/10.1016/j.ajoc.2016.07.004 CrossRefPubMedPubMedCentral

50.

Perrone S, Rossetti A, Sportiello P, Mirabelli P, Cimatti P, Doro D (2016) Coats’ disease: very long-term outcome after early stage conventional treatment. Open Ophthalmol J10:22–26. https://doi.org/10.2174/1874364101610010022 CrossRef

51.

Adam RS, Kertes PJ, Lam WC (2007) Observations on the management of Coats’ disease: less is more. Br J Ophthalmol 91:303–306CrossRefPubMed

52.

Pesch KJ, Meyer-Schwickerath G (1967) Light coagulation in morbus Coats and Leber’s retinitis. Klin Monbl Augenheilkd 151:846–853. https://doi.org/10.1136/bjo.2006.103382 CrossRefPubMed

53.

Ridley ME, Shields JA, Brown GC, Tasman W (1982) Coats’ disease. Evaluation of management. Ophthalmology 89:1381. https://doi.org/10.1016/S0161-6420(82)34634-5 CrossRefPubMed

54.

Nucci P, Bandello F, Serafino M, Wilson ME (2002) Selective photocoagulation in Coats disease: ten-year follow-up. Eur J Ophthalmol 12:501–505. https://doi.org/10.1177/112067210201200609 CrossRefPubMed

55.

Shapiro MJ, Chow CC, Karth PA, Kiernan DF, Blair MP (2011) Effects of green diode laser in the treatment of pediatric Coats disease. Am J Ophthalmol 151:725–731.e722. https://doi.org/10.1016/j.ajo.2010.10.024 CrossRefPubMed

56.

Levinson JD (2015) 577-nm yellow laser photocoagulation for Coats disease. Retina 36:1388. https://doi.org/10.1097/IAE.0000000000000874 CrossRef

57.

Xuan C, Zhao P, Qi Z, Jin H (2015) Treatment of stage 3 Coats’ disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach. Graefes Arch Clin Exp Ophthalmol 253:999. https://doi.org/10.1007/s00417-015-2984-4 CrossRef

58.

Stanga PE, Jaberansari H, Bindra MS, Gil-Martinez M, Biswas S (2016) Transcleral drainage of subretinal fluid, anti-vascular endothelial growth factor, and wide-field imaging-guided laser in coats exudative retinal detachment. Retina 36:156–162. https://doi.org/10.1097/IAE.0000000000000669 CrossRefPubMed

59.

Karacorlu M, Hocaoglu M, Sayman MI, Arf S (2017) Long-term anatomical and functional outcomes following vitrectomy for advanced Coats disease. Retina 37:1757. https://doi.org/10.1097/IAE.0000000000001415 CrossRefPubMed

60.

Ogata M, Suzuki T, Nakagawa Y, Hayakawa K, Kawai K (2014) Post-vitrectomy observation of Coat’s disease associated with exudative retinal detachment, successfully treated with long-term silicone oil tamponade. Tokai J Exp Clin Med 39:25–28PubMed

61.

Li AS, Capone A Jr, Trese MT, Sears JE, Kychenthal A, De la Huerta I et al (2018) Long-term outcomes of total exudative retinal detachments in stage 3B Coats disease. Ophthalmology 125:887–893. https://doi.org/10.1016/j.ophtha.2017.12.010 CrossRefPubMed

62.

Imaizumi A, Kusaka S, Takaesu S, Sawaguchi S, Shimomura Y (2016) Subretinal fluid drainage and vitrectomy are helpful in diagnosing and treating eyes with advanced Coats’ disease. Case Rep Ophthalmol 7:223–229. https://doi.org/10.1159/000445795 CrossRefPubMedPubMedCentral

63.

Suesskind D, Altpeter E, Schrader M, Bartzschmidt KU, Aisenbrey S (2014) Pars plana vitrectomy for treatment of advanced Coats’ disease–presentation of a modified surgical technique and long-term follow-up. Graefes Arch Clin Exp Ophthalmol 252:873. https://doi.org/10.1007/s00417-013-2512-3 CrossRefPubMed

64.

Mino A, Mitamura Y, Katome T, Semba K, Egawa M, Naito T (2015) Case of adult-onset Coats’ disease with epiretinal membrane treated with 25-gauge pars plana vitrectomy. J Med Investig JMI 62:85–88. https://doi.org/10.2152/jmi.62.85 CrossRef

65.

Ramasubramanian A, Shields CL (2012) Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 96:356. https://doi.org/10.1136/bjophthalmol-2011-300141 CrossRefPubMed

66.

Sun Y, Jain A, Moshfeghi DM (2007) Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol 245:1387–1388. https://doi.org/10.1007/s00417-007-0559-8 CrossRefPubMed

67.

He YG, Wang H, Zhao B, Lee J, Bahl D, Mccluskey J (2010) Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol 248:1519–1521. https://doi.org/10.1007/s00417-010-1366-1 CrossRefPubMed

68.

Kaul S, Uparkar M, Mody K, Walinjkar J, Kothari M, Natarajan S (2010) Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol 58:76–78. https://doi.org/10.4103/0301-4738.58480 CrossRefPubMedPubMedCentral

69.

Giannakopoulos M, Drimtzias E, Panteli V, Vasilakis P, Gartaganis SP (2017) Intravitreal ranibizumab as an adjunctive treatment for Coats disease (6-year follow-up). Retin Cases Brief Rep 11:339–343. https://doi.org/10.1097/icb.0000000000000363 CrossRefPubMed

70.

Kam AW, Hui M, Cherepanoff S, Fung AT (2018) Rapid “epiretinal membrane” development following intravitreal bevacizumab for Coats’ disease. Am J Ophthalmol Case Rep 11:75–77. https://doi.org/10.1016/j.ajoc.2018.06.002 CrossRefPubMedPubMedCentral

71.

Villegas VM, Gold AS, Berrocal AM, Murray TG (2014) Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation. Clin Ophthalmol 8:973–976. https://doi.org/10.2147/OPTH.S62816 CrossRefPubMedPubMedCentral

72.

Li S, Deng G, Liu J, Ma Y, Lu H (2017) The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease. BMC Ophthalmol 17:76. https://doi.org/10.1186/s12886-017-0469-4 CrossRefPubMedPubMedCentral

73.

Lin CJ, Hwang JF, Chen YT, Chen SN (2010) The effect of intravitreal bevacizumab in the treatment of Coats’ disease in children. Retina 30:617–622. https://doi.org/10.1097/iae.0b013e318203c01e CrossRefPubMed

74.

Lin CJ, Chen SN, Hwang JF, Yang CM (2013) Combination treatment of pediatric coats’ disease: a bicenter study in Taiwan. J Pediatr Ophthalmol Strabismus 50:356–362. https://doi.org/10.3928/01913913-20131125-02 CrossRefPubMed

75.

Fiorentzis M, Stavridis E, Seitz B, Viestenz A (2015) Adjuvant anti-VEGF therapy in Coats’ disease. Ophthalmologe 112:451–454. https://doi.org/10.1007/s00347-014-3122-0 CrossRefPubMed

76.

Park S, Cho HJ, Lee DW, Kim CG, Kim JW (2015) Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats’ disease. Graefe’s Arch Clin Exp Ophthalmol 254:1511–1517. https://doi.org/10.1007/s00417-015-3233-6 CrossRef

77.

Kodama A, Sugioka K, Kusaka S, Matsumoto C, Shimomura Y (2014) Combined treatment for Coats’ disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases. BMC Ophthalmol 14:36. https://doi.org/10.1186/1471-2415-14-36 CrossRefPubMedPubMedCentral

78.

Gaillard MC, Mataftsi A, Balmer A, Houghton S, Munier FL (2014) ranibizumab in the management of advanced Coats disease Stages 3B and 4: long-term outcomes. Retina 34:2275–2281. https://doi.org/10.1097/IAE.0000000000000248 CrossRefPubMed

79.

Shieh WS, Shah GK, Blinder KJ (2017) Coats’ disease-related macular edema treated with combined aflibercept and laser photocoagulation. Case Rep Ophthalmol Med 2017:2824874. https://doi.org/10.1155/2017/2824874 CrossRefPubMedPubMedCentral

80.

Yang Q, Wei W, Shi X, Yang L (2016) Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats’ disease. Acta Ophthalmol 94:401–406. https://doi.org/10.1111/aos.13067 CrossRefPubMed

81.

Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F et al (2005) Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46:1440–1444. https://doi.org/10.1167/iovs.04-0905 CrossRefPubMed

82.

Sebastián MC, Roberto GP, Rosa DM, Cristina ML, Manuel DL (2012) Adult Coats’ disease successfully managed with the dexamethasone intravitreal implant (Ozurdex^®) combined with retinal photocoagulation. Case Rep Ophthalmol 3:123–127. https://doi.org/10.1159/000337481 CrossRef

83.

Bergstrom CS, Rd HG (2008) Combination intravitreal triamcinolone injection and cryotherapy for exudative retinal detachments in severe Coats disease. Retina 28:33–37. https://doi.org/10.1097/iae.0b013e318159ecad CrossRef

84.

Othman IS, Moussa M, Bouhaimed M (2010) Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol 94:606–610. https://doi.org/10.1097/IAE.0b013e318159ecad CrossRefPubMed

85.

Osman SA, Can DH, Aylin Y (2013) Intravitreal dexamethasone implant (Ozurdex) in Coats’ disease. Case Rep Ophthalmol 4:122–128. https://doi.org/10.1007/s00417-012-2249-4 CrossRef

86.

Kumar K, Raj P, Chandnani N, Agarwal A (2018) Intravitreal dexamethasone implant with retinal photocoagulation for adult-onset Coats’ disease. Int Ophthalmol. https://doi.org/10.1007/s10792-018-0827-0 CrossRefPubMed

Title: Recent advances in the diagnosis and treatment of Coats’ disease
Publication date: 01-04-2019
Keywords: Cryotherapy
Cryotherapy
Retinal Detachment
Vitrectomy
Bevacizumab
Laser
Published in: International Ophthalmology / Issue 4/2019
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-019-01095-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Recent advances in the diagnosis and treatment of Coats’ disease

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

Contrast sensitivity of patients with congenital color vision deficiency

Factors associated with corneal epithelial defects after pars plana vitrectomy

Epithelial map-guided anterior stromal micropuncture for the treatment of recurrent corneal erosion syndrome

Decompression retinochoroidopathy: a unique presentation post-trabeculectomy

Novel grid and sectoral analyses in monitoring corneal scars

Long-term evaluation of ocular hypertension with primary angle closure and primary open angles